Aflibercept patent expiry?

Question

Accepted Answer

Aflibercept (Eylea®) – Patent Landscape & Where the Clock is At

Category	Key Patent(s)	Filing / Grant Date	20‑Year Term	Expiry (U.S.)
Composition (fusion protein)	US 7,041,761 – “Fusion protein containing VEGF‑binding domains linked to an Fc fragment”	Filed 2003	20 years	2023
	US 6,030,466 – “Fusion protein comprising VEGF‑binding domains”	Filed 2000	20 years	2020
	US 5,887,589 – “Fusion protein of VEGF receptors”	Filed 1998	20 years	2018
Use (ocular indications)	US 8,059,322 – “Use of aflibercept for treatment of eye diseases”	Filed 2010	20 years	2030
	US 8,386,947 – “Method of treating wet age‑related macular degeneration”	Filed 2010	20 years	2030
Formulation / Manufacturing	US 9,314,860 – “Process for making aflibercept”	Filed 2012	20 years	2032
Device / Delivery	US 8,982,567 – “Device for delivering aflibercept intravitreally”	Filed 2011	20 years	2031

What’s expired	What’s still active	Implication
Composition patents (US 7,041,761, US 6,030,466, US 5,887,589)	Use patents (US 8,059,322, US 8,386,947)	You can no longer “copy” the protein itself after 2023, but you can’t use aflibercept for wet AMD or other eye indications without infringing a still‑alive use patent.
Patent on the exact manufacturing process (US 9,314,860)	Formulation/Delivery patents (US 8,982,567)	Even if you had the right to make the protein, you might still need a license to use the specific ocular formulation or injection device.

Ask Questions, Get Industry Insights … Instantly